BerGenBio ASA BGBIO.OL Stock
BerGenBio ASA Price Chart
BerGenBio ASA BGBIO.OL Financial and Trading Overview
| BerGenBio ASA stock price | 0.16 NOK |
| Previous Close | 0.31 NOK |
| Open | 0.32 NOK |
| Bid | 0.31 NOK x 0 |
| Ask | 0.3 NOK x 0 |
| Day's Range | 0.27 - 0.32 NOK |
| 52 Week Range | 0.25 - 14.9 NOK |
| Volume | 2.03M NOK |
| Avg. Volume | 2.24M NOK |
| Market Cap | 32.81M NOK |
| Beta (5Y Monthly) | 1.884291 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.55 NOK |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.22 NOK |
BGBIO.OL Valuation Measures
| Enterprise Value | -122954576 NOK |
| Trailing P/E | N/A |
| Forward P/E | -1.0306451 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 84.343895 |
| Price/Book (mrq) | 0.32014027 |
| Enterprise Value/Revenue | -316.079 |
| Enterprise Value/EBITDA | 0.402 |
Trading Information
BerGenBio ASA Stock Price History
| Beta (5Y Monthly) | 1.884291 |
| 52-Week Change | -97.18% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 14.9 NOK |
| 52 Week Low | 0.25 NOK |
| 50-Day Moving Average | 2.25 NOK |
| 200-Day Moving Average | 5.86 NOK |
BGBIO.OL Share Statistics
| Avg. Volume (3 month) | 2.24M NOK |
| Avg. Daily Volume (10-Days) | 4.84M NOK |
| Shares Outstanding | 102.69M |
| Float | 51.88M |
| Short Ratio | N/A |
| % Held by Insiders | 34.58% |
| % Held by Institutions | 18.92% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -78569.14% |
| Gross Margin | 100.00% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -61.92% |
| Return on Equity (ttm) | -127.76% |
Income Statement
| Revenue (ttm) | 389K NOK |
| Revenue Per Share (ttm) | 0.004 NOK |
| Quarterly Revenue Growth (yoy) | -49.70% |
| Gross Profit (ttm) | 389K NOK |
| EBITDA | -305553984 NOK |
| Net Income Avi to Common (ttm) | -302121984 NOK |
| Diluted EPS (ttm) | -2.86 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 150.8M NOK |
| Total Cash Per Share (mrq) | 1.7 NOK |
| Total Debt (mrq) | 275K NOK |
| Total Debt/Equity (mrq) | 0.31 NOK |
| Current Ratio (mrq) | 2.139 |
| Book Value Per Share (mrq) | 0.998 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -288231008 NOK |
| Levered Free Cash Flow (ttm) | -176587872 NOK |
Profile of BerGenBio ASA
| Country | Norway |
| State | N/A |
| City | Bergen |
| Address | Møllendalsbakken 9 |
| ZIP | 5009 |
| Phone | 47 55 96 11 59 |
| Website | https://www.bergenbio.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 29 |
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of novel medicines to treat immune-evasive, drug resistant, and metastatic cancers; and respiratory diseases. It develops bemcentinib, an oral once-a-day inhibitor of AXL receptor tyrosine kinase, which is in Phase 1b/2a clinical trial to treat non-small cell lung cancer, and Phase 2 clinical trial to treat acute myeloid leukemia and COVID-19. Bemcentinib is also being studied for glioblastoma, 2L lung cancer, melanoma, pancreatic cancer, and mesothelioma. In addition, the company is developing tilvestamab, an anti-AXL function-blocking monoclonal antibody that is in Phase 1b clinical trial for the treatment of ovarian cancer; and mipasetamab uzoptirine, which is in Phase 1 clinical trial for the treatment of solid tumors. It has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.
Q&A For BerGenBio ASA Stock
What is a current BGBIO.OL stock price?
BerGenBio ASA BGBIO.OL stock price today per share is 0.16 NOK.
How to purchase BerGenBio ASA stock?
You can buy BGBIO.OL shares on the Oslo exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for BerGenBio ASA?
The stock symbol or ticker of BerGenBio ASA is BGBIO.OL.
Which industry does the BerGenBio ASA company belong to?
The BerGenBio ASA industry is Biotechnology.
How many shares does BerGenBio ASA have in circulation?
The max supply of BerGenBio ASA shares is 2.69B.
What is BerGenBio ASA Price to Earnings Ratio (PE Ratio)?
BerGenBio ASA PE Ratio is now.
What was BerGenBio ASA earnings per share over the trailing 12 months (TTM)?
BerGenBio ASA EPS is -0.55 NOK over the trailing 12 months.
Which sector does the BerGenBio ASA company belong to?
The BerGenBio ASA sector is Healthcare.
BerGenBio ASA BGBIO.OL included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| Oslo Bors All-Share Index_GI OSEAX | 1017.37 NOK 97.59 USD |
+1.04
|
371.46M NOK 35.63M USD | 1003.3 NOK 96.24 USD | 1018.4 NOK 97.69 USD | — - | 371.46M NOK 35.63M USD |
- {{ link.label }} {{link}}